Simulations Plus, Inc. (NASDAQ:SLP) Files An 8-K Other Events
Item 8.01Other Events
On January 9, 2017, Simulations Plus, Inc., a California
corporation (the Company), issued a press release announcing
financial results for its first quarter of FY2017 ended November
30, 2016. The press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
On January 9, 2017, Simulations Plus, Inc., a California
corporation (the Company), held an investor conference call
reporting its financial results for first quarter of FY2017 ended
November 30, 2016. The PowerPoint slides, which were used for
this Investor Conference Call, are attached herein as exhibit
99.2 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K
shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall such information be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended (the
Securities Act), or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The
information set forth in this Current Report on Form 8-K shall
not be deemed an admission as to the materiality of any
information in this report on Current Report on Form 8-K that is
required to be disclosed solely to satisfy the requirements of
Regulation FD.
This report on Form 8-K (the Report), including the disclosures
set forth herein, contains certain forward-looking statements
that involve substantial risks and uncertainties. When used
herein, the terms anticipates, expects, estimates, believes and
similar expressions, as they relate to us or our management, are
intended to identify such forward-looking statements.
Forward-looking statements in this Report or hereafter, including
in other publicly available documents filed with the Securities
and Exchange Commission (the Commission), reports to the
stockholders of Simulations Plus, Inc., a California corporation
(the Company or us, our or we) and other publicly available
statements issued or released by us involve known and unknown
risks, uncertainties and other factors which could cause our
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. Such future results are based
upon management’s best estimates based upon current conditions
and the most recent results of operations. These risks include,
but are not limited to, the risks set forth herein and in such
other documents filed with the Commission, each of which could
adversely affect our business and the accuracy of the
forward-looking statements contained herein. Our actual results,
performance or achievements may differ materially from those
expressed or implied by such forward-looking statements.
Item 9.01Financial Statements and Exhibits
(d)Exhibits
| 99.1 | Press release issued on January 9, 2017. |
| 99.2 |
PowerPoint presentation at the Investor Conference Call on January 9, 2017. |
About Simulations Plus, Inc. (NASDAQ:SLP)
Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs. Simulations Plus, Inc. (NASDAQ:SLP) Recent Trading Information
Simulations Plus, Inc. (NASDAQ:SLP) closed its last trading session up +0.45 at 10.00 with 83,434 shares trading hands.
